Contemporary Management of ST-Elevation Myocardial Infarction

详细信息    查看全文

• 作者：Ashleigh Dind ; MBBS^a ; Usaid Allahwala ; MBBS ; BSc(Med)^a ; Kaleab N. Asrress ; MA ; BM BCh ; MRCP ; PhD^a ; Sanjit S. Jolly ; MD ; MSc ; FRCPC^b ; Ravinay Bhindi ; MBBS ; PhD ; FRACP ; FESC^a ; ^{ravinay.bhindi@sydney.edu.au}
• 关键词：ST-Elevation Myocardial Infarction ; P2Y12 inhibitors ; Thrombus aspiration ; Non-culprit artery
• 刊名：Heart, Lung and Circulation
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：26
• 期：2
• 页码：114-121
• 全文大小：608 K
• 卷排序：26

文摘

Recent advances have caused a major shift in the way ST-elevation myocardial infarctions are managed. This review explores the pharmacological and interventional techniques that have evidence for improving outcomes and the landmark trials that have sparked change. The new P2Y12 inhibitors, ticagrelor and prasugrel, have been shown to be superior to clopidogrel in STEMI patients undergoing primary percutaneous coronary intervention. Concurrently, many technical aspects of percutaneous coronary intervention have been further clarified by trial data, with bare-metal stents, routine thrombus aspiration and femoral access showing evidence of inferiority. Ongoing trials will provide more information on the role of non-culprit lesion PCI, bioresorbable vascular scaffolds, mechanical devices in persistent ischaemia and early automatic implantable cardioverter-defibrillators for inducible ventricular tachycardia.